Recently, MSCI, an international authoritative index company, updated the environmental, social and governance (ESG) rating report for Hansoh Pharma (the "Company"). With its excellent performance in product safety and quality, talent development, corporate governance and other aspects, Hansoh Pharma's ESG rating has been upgraded from BBB to A.
MSCI, as the world's largest index provider, rates 8,500 companies (14,000 issuers including subsidiaries) and more than 680,000 equity and fixed income securities globally on ESG, aiming at helping international investors assess the ESG risk management capability and investment value of each company. The upgrade of Hansoh Pharma's ESG rating to A by MSCI this time is a recognition of the Company's efforts in sustainability and ESG aspects, and a high affirmation of its long-term investment value.
In the latest MSCI ESG rating, Hansoh Pharma has been recognized for its management and performance on issues such as human capital management and product safety and quality:
The Company always adheres to the "people-oriented" approach, providing comprehensive development channels for employees and protecting their rights and interests;
In terms of product safety and quality, the Company adheres to the quality policy of "all-member engagement, full process and continuous improvement", and establishes a quality control system throughout the life cycle from product R&D to production and further to marketing, so as to protect people's health with accessible, affordable and reliable quality drugs.
Also, the Company attaches great importance to environmental protection, and lives up to its low-carbon, environmental protection and green development commitments by establishing and improving the environmental index management system.
As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma has been working on the innovative path towards sustainable development all along. It attaches great importance to all aspects of ESG management, keeps improving its ESG performance in terms of corporate governance and behavior, product safety and quality, human resource development, environmental protection, and corporate social responsibility, and embeds the ESG concept in all aspects of corporate strategy, production and operation, so as to build up the Company's competitiveness in sustainable development. Previously, Hansoh Pharma's ESG report in 2020 received an "AA" rating from the International Forum on Corporate Social Responsibility of Industry and Information Technology Enterprises co-sponsored by the Ministry of Industry and Information Technology of China and the United Nations Global Compact.
As a global corporate citizen, Hansoh Pharma will continue to improve its ESG performance by further strengthening the ESG management structure, enhancing ESG information disclosure, and accelerating innovation and R&D efforts. The Company will always adhere to the sustainable development strategy, and while continuing to improve the availability of drugs, it will better fulfill its commitments to customers, employees, investors, society and the environment, and further contribute to the sustainable development of the Company and the society.
